If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Five recognized "nuclear-weapon states" under the terms of the Nuclear Non-Proliferation Treaty (NPT): the United States (first nuclear weapon tested and two bombs used as weapons in 1945), Russia (first weapon tested in 1949), the United Kingdom (1952), France (1960), and China (1964) Three other declared nuclear states that are not signatories of the NPT: India (not a signatory, weapon tested in 1974), Pakistan (not a signatory, weapon tested in 1998), and North Korea (withdrew from the NPT in 2003, weapon tested in 2006) Israel, which is widely known to have developed nuclear weapons (likely first tested in the 1960s or 1970s) but has not openly declared its capability South Africa, which also had enrichment capabilities and developed nuclear weapons (possibly tested in 1979), but disassembled its arsenal and joined the NPT in 1991
U+039B Λ GREEK CAPITAL LETTER LAMDA (Λ) U+03BB λ GREEK SMALL LETTER LAMDA (λ) U+1D27 ᴧ GREEK LETTER SMALL CAPITAL LAMDA U+2C96 Ⲗ COPTIC CAPITAL LETTER LAULA U+2C97 ⲗ COPTIC SMALL LETTER LAULA U+A7DA LATIN CAPITAL LETTER LAMBDA U+A7DB LATIN SMALL LETTER LAMBDA U+1038D 𐎍 UGARITIC LETTER LAMDA U+1D6B2 𝚲 MATHEMATICAL BOLD CAPITAL LAMDA U+1D6CC 𝛌 MATHEMATICAL BOLD SMALL LAMDA U+1D6EC 𝛬 MATHEMATICAL ITALIC CAPITAL LAMDA U+1D706 𝜆 MATHEMATICAL ITALIC SMALL LAMDA U+1D726 𝜦 MATHEMATICAL BOLD ITALIC CAPITAL LAMDA U+1D740 𝝀 MATHEMATICAL BOLD ITALIC SMALL LAMDA U+1D760 𝝠 MATHEMATICAL SANS-SERIF BOLD CAPITAL LAMDA U+1D77A 𝝺 MATHEMATICAL SANS-SERIF BOLD SMALL LAMDA U+1D79A 𝞚 MATHEMATICAL SANS-SERIF BOLD ITALIC CAPITAL LAMDA U+1D7B4 𝞴 MATHEMATICAL SANS-SERIF BOLD ITALIC SMALL LAMDA
On 20 February 1990 the Volkskammer passed a new electoral law, reducing it in size to 400 members elected via party-list proportional representation, with no electoral threshold. Joint lists between parties were allowed, and a number of parties formed alliances for the election, including the Association of Free Democrats, Alliance 90, and an alliance between the Green Party and Independent Women's Association. Seats were calculated nationally using the largest remainder method, and distributed in multi-member constituencies corresponding to the fifteen Bezirke.
Among psychotropic drugs, chlorpromazine is known to cause cholestatic hepatitis. Tricyclic antidepressants (imipramine, amitriptyline) and SSRIs (duloxetine) causing cholestasis have also been reported. Anti-inflammatory drugs with cholestatic potential include the immunosuppressant azathioprine, which has been reported to cause fatal cholestatic hepatitis, and the NSAID diclofenac.
Sources: en.wikipedia.org
==== Radial glial cells ==== The radial glial cells are disposed in planes perpendicular to the axes of ventricles. One of their processes abuts the pia mater, while the other is deeply buried in grey matter. Radial glia are mostly present during development, playing a role in neuron migration. Müller cells of the retina and Bergmann glia cells of the cerebellar cortex represent an exception, being present still during adulthood. When in proximity to the pia mater, all three forms of astrocytes send out processes to form the pia-glial membrane.
Autosomal dominant: heart problems with weakness (and wasting) of skeletal muscles and Achilles tendon contractures. X-linked: result of the EMD gene mutation, characterized by cardiac involvement. Autosomal recessive: characterized by cardiac issues, such as arrhythmia.
== Other Activities == 1972–1975 – Associate Member, Viking Lander Science Team, NASA 1979–1982 – – Member, Committee on Response Strategies to Unusual Chemical Hazards, Assembly of Life Sciences, National Research Council 1982 – U.S. Coordinator, U.S.-Japan Joint Seminar on “Microcolumn Separation Methods and their Ancillary Techniques,” Honolulu, Hawaii 1980–1984 – Member, Advisory Committee to the Analytical Chemistry Division, Oak Ridge National Laboratory 1986 – Instructor, ACS Short Course on Supercritical Fluid Chromatography 1988, 1990 – Organizing Committee, International Symposium, “Microcolumn Separation Methods,” Bloomington, IN and Aronberg, Sweden 1988, 1991 – Scientific Committee, International Symposium, “HPLC 88” and “HPLC 92” 1977–Pres. – Instructor, ACS Short Course on Capillary Gas Chromatography 1978–Pres. – ACS Lecture Tour Speaker 1990–Pres. – Scientific Committee, International Symposia on Capillary Chromatography 1994 – Scientific Committee, Glycobiology: Analytical Methods 2003 – Member of the Center for the Integrative Study of Animal Behavior, Indiana University 2004 – Member of the Indiana University Cancer Center, IU School of Medicine .
====== Glycerin ====== Glycerin (often called vegetable glycerin, or VG) was long thought to be a safe option. However, the carcinogen formaldehyde is known as an impurity found in propylene glycol and glycerol vapor degradation.
downregulation Also repression or suppression. Any process, natural or artificial, which decreases the level of gene expression of a certain gene. A gene which is observed to be expressed at relatively low levels (such as by detecting lower levels of its mRNA transcripts) in one sample compared to another sample is said to be downregulated. Contrast upregulation.
Sources: en.wikipedia.org
Since AlphaFold outputs protein coordinates directly, AlphaFold produces predictions in graphics processing unit (GPU) minutes to GPU hours, depending on the length of protein sequence. The European Bioinformatics Institute together with DeepMind have constructed the AlphaFold – EBI database for predicted protein structures.
=== Recombinant === The production of recombinant monoclonal antibodies involves repertoire cloning, CRISPR/Cas9, or phage display/yeast display technologies. Recombinant antibody engineering involves antibody production by the use of viruses or yeast, rather than mice. These techniques rely on rapid cloning of immunoglobulin gene segments to create libraries of antibodies with slightly different amino acid sequences from which antibodies with desired specificities can be selected. The phage antibody libraries are a variant of phage antigen libraries. These techniques can be used to enhance the specificity with which antibodies recognize antigens, their stability in various environmental conditions, their therapeutic efficacy and their detectability in diagnostic applications. Fermentation chambers have been used for large scale antibody production.
A later vertebrate study identified protein tyrosine phosphatase receptor F (PTPRF), a member of the LAR family, as a conserved cognate receptor for the glucogenic actions of asprosin. In zebrafish, two Ptprf paralogs (ptprfa/b) are expressed in liver, bind asprosin with nanomolar affinity, and are required for asprosin-induced hyperglycemia and upregulation of gluconeogenic genes; soluble Ptprf ligand-binding domains neutralize the glucogenic effects and lower basal glucose, while ptprfa/b knockout fish show hypoglycemia and a blunted response to asprosin but normal responses to glucagon. In mice, PTPRF is expressed in liver and binds asprosin; Ptprf-deficient animals exhibit impaired asprosin-induced glucose production and reduced hepatic G6pc and Pck1 induction, and Ptprf deletion improves glucose tolerance without altering Olfr734 expression. Mechanistically, the same study showed that asprosin promotes insulin receptor and Akt dephosphorylation via PTPRF, counteracting insulin's suppression of gluconeogenesis and suggesting that chronic asprosin–PTPRF signaling contributes to hepatic insulin resistance. Several other independent studies have confirmed asprosin's glucogenic function.
==== Documentaries ==== The BBC interviewed Jung for Face to Face with John Freeman at Jung's home in Zurich in 1959. Stephen Segaller produced a documentary on Jung as part of his "World of Dreams", Wisdom of the Dream in 1985. It was re-issued in 2018. It was followed by a book of the same title. Matter of Heart (1986) is a documentary about Jung featuring interviews with those who knew him and archival footage. On 2 December 2004, BBC Radio 4's In Our Time broadcast a program on "the mind and theories" of Jung.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.